Award task order: "dosage form development, manufacture, and stability studies of metarrestin (ML246)" under contract: "CRO support for ncats drug product development, manufacture, and stability…
Ended Awarded Last action
- Contract number
- HHSN27100001
- Awardee
-
Societal Cdmo San Diego, LLC UEI YRPTVKHDL7Z5 Part of Recro Pharma, Inc.
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $494,300
Award facts
- Opportunity
-
- CRO Support for NCATS Drug Product Development, Manufacture, and Stability Studies Pre-Solicitation · N01TR172003 · Posted Jul 21, 2016
- Contract value 100% obligated
- $494,300.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$4,000 | |
| Supplemental Agreement for work within scope | $27,000 | |
| Supplemental Agreement for work within scope | $9,000 | |
| Exercise an Option | $23,000 | |
| Supplemental Agreement for work within scope | $10,000 | |
| Supplemental Agreement for work within scope | $2,300 | |
| Supplemental Agreement for work within scope | $107,659 | |
| Original award | $319,341 |
About this award
This is a delivery order awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Societal CDMO San Diego, LLC, a small disadvantaged business contract development and manufacturing organization (CDMO). The $494,300 firm-fixed-price task order is for dosage form development, manufacture, and stability studies of the investigational compound metarrestin (ML246) under the larger "CRO Support for NCATS Drug Product Development, Manufacture, and Stability Studies" indefinite delivery, indefinite quantity (IDIQ) contract. As a division of Recro Pharma, Inc., Societal CDMO San Diego has expertise in providing pharmaceutical research services to federal agencies, including the Department of Health and Human Services and Department of Veterans Affairs, across various dosage forms.
Description
Award task order: "dosage form development, manufacture, and stability studies of metarrestin (ML246)" under contract: "CRO support for ncats drug product development, manufacture, and stability studies"
Quick answers
Who was awarded contract HHSN27100001?
HHSN27100001 was awarded to Societal Cdmo San Diego, LLC by National Institute on Drug Abuse (National Institutes of Health) on September 14, 2017.
How much is contract HHSN27100001 worth?
The government has obligated $494,300 on HHSN27100001.
Which agency awarded contract HHSN27100001?
National Institute on Drug Abuse (National Institutes of Health) awarded HHSN27100001, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract HHSN27100001 an order under another contract?
Yes. HHSN27100001 is a delivery order under HHSN271201700020I, an indefinite delivery contract, on NCATS Drug Product Development Studies 2017-2022.
Was contract HHSN27100001 competed?
The extent of competition for HHSN27100001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award